Semaglutide injections reversed some cases of MASH liver disease in clinical trials, reducing inflammation in 62.9% of ...

An international study reveals that the drug can reverse liver damage in patients. An international study led by researchers ...

A new study suggests that semaglutide, the active ingredient in Ozempic, may help decrease liver fat, inflammation, and ...

Semaglutide and similar GLP-1 drugs are poised to become frontline treatments for a severe form of liver disease.

Promising results from a phase 2 study prompted the ongoing phase 3 ESSENCE trial, to evaluate the GLP-1 receptor agonist semaglutide in patients with MASH and stage 2 or 3 fibrosis. Sanyal et al.

Fat cells are also metabolically active and can cause a chronic state of inflammation in the part of the body where they ...

A study in weight loss drugs where one third of participants were given a placebo turned out to have some impressive results.

Semaglutide significantly improved liver fibrosis and steatohepatitis resolution in MASH patients over 72 weeks compared to placebo. The study involved 800 patients receiving semaglutide and 400 ...

Altimmune nears a key MASH trial readout, with strong market potential and new liver and alcohol studies supporting growth.

More than half of adults with MASH receiving semaglutide had resolution of steatohepatitis at 72 weeks. A reduction in liver fibrosis stage was observed among 36.8% of the semaglutide group.

The active ingredient in the popular weight loss drug Wegovy may help treat a type of fatty liver disease, according to a new study published Wednesday.